Why M&A Activity Is Set to Accelerate
Big‑pharma players are stacking cash reserves to mitigate the impact of looming patent expiries. The latest M&A analytics show average deal sizes hovering around $2 billion – a clear shift from the high‑volume, low‑value deals of previous years. Executives see acquisitions as the quickest route to replenish pipelines and protect revenue streams.
Strategic buying over organic growth
Organic R&D pipelines often require a decade before they become market‑ready, while a well‑priced acquisition can deliver immediate access to late‑stage assets. Companies such as Johnson & Johnson, Novartis and Merck have demonstrated this with multi‑billion‑dollar purchases of neuroscience and RNA‑focused firms.
The Patent Cliff: A Catalyst for Strategic Acquisitions
By 2030, fewer than 5 % of global drug sales will remain under patent protection, according to a recent GlobalData forecast. This “patent cliff” creates a vacuum that companies are scrambling to fill.
Key example: Merck’s flagship oncology drug Keytruda is set to lose core US exclusivity within the next three years. The anticipated revenue dip has already spurred a wave of partnership talks and acquisition bids.
How firms are responding
- Boosting external innovation through licensing and joint‑venture agreements.
- Targeting late‑stage candidates that can be commercialized quickly.
- Increasing R&D spend on next‑generation modalities such as gene‑editing and RNA therapeutics.
Neuroscience Takes Center Stage Over Oncology
In the United States, the CNS/neurology therapeutic area now eclipses oncology in total M&A value, capturing over $30 billion last year. The shift reflects two forces:
- A growing patient pool for disorders like depression, bipolar disorder and Alzheimer’s disease.
- Relatively immature competition compared with the crowded oncology space.
Real‑life case: Johnson & Johnson’s $14.6 billion acquisition of Intra‑Cellular Therapeutics brought the FDA‑approved drug Caplyta into a broader indication for major depressive disorder, positioning it as a potential $5 billion revenue generator.
Weight‑Loss and Metabolic Therapies: The New Deal Drivers
GLP‑1 receptor agonists have reshaped the M&A landscape. A high‑profile bidding war saw Pfizer secure Metsera for $10 billion, highlighting how obesity treatments are now considered “blockbuster” assets.
Did you know? Sales of top‑selling weight‑loss drugs have grown at an annual compound rate of 38 % over the past five years, outpacing traditional oncology growth.
Impact on market caps
Eli Lilly’s market valuation breached the $1 trillion mark, largely driven by its obesity portfolio, underscoring the financial muscle of metabolic therapies.
Milestone Payments and CVRs: De‑Risking the Deal Landscape
Deal structures in 2025 leaned heavily on performance‑based components. Average milestone payments surged by 255 % in Q4, while Contingent Value Rights (CVRs) appeared in high‑profile deals such as Pfizer‑Metsera and Roche‑89bio.
Pro tip: When evaluating a potential acquisition, scrutinize the breakdown of upfront cash versus milestone tranches. A balanced structure can protect your investment if the target fails to meet clinical endpoints.
From financial to operational milestones
Companies now tie payouts to tangible operational outcomes – like market launch dates or sales thresholds – rather than purely financial metrics. This trend aligns incentives and narrows valuation gaps between buyer and seller.
China’s Growing Influence in Global Pharma Deals
Chinese biotech firms now contribute to roughly 20 % of the world’s drug development pipeline. Licensing agreements between U.S. and Chinese companies rose 280 % between 2020 and 2024.
Key insight: While China offers a rich source of early‑stage innovation, the pool of “obvious” deals may thin out by 2026, prompting firms to look for deeper, more differentiated assets.
Strategic considerations
- Establish robust IP protection frameworks when collaborating with Chinese partners.
- Leverage local regulatory expertise to accelerate market entry.
- Balance short‑term licensing gains with long‑term equity investments for sustained growth.
What to Expect at the Next JP Morgan Healthcare Conference
The upcoming JP Morgan Healthcare Conference will serve as a barometer for the direction of pharma M&A in 2026. Attendees will watch for signals on:
- Whether neuroscience continues to dominate deal flow.
- Emerging interest in gene‑therapy and CAR‑T platforms.
- New financing structures that may incorporate hybrid milestone‑CVR models.
Industry leaders are also expected to showcase pipeline updates for late‑stage assets that could become the next “blockbuster” acquisitions.
FAQ
- What is a “patent cliff”?
- A period when a large number of high‑revenue drugs lose exclusive patent protection, forcing companies to seek new sources of revenue.
- Why are milestone payments increasing?
- Dealmakers use them to share risk, ensuring sellers receive additional value only if the product hits predefined clinical or commercial goals.
- How important is China for future pharma deals?
- China supplies a significant share of early‑stage innovation and will remain a key partner, though the pace of large‑scale deals may moderate.
- What therapeutic area is currently leading M&A value in the U.S.?
- The CNS/neurology segment, surpassing oncology in total deal value.
Take the Next Step
What trends will shape your company’s M&A strategy? Share your thoughts in the comments below, explore our latest innovation reports, and subscribe to our newsletter for real‑time updates on the fast‑moving pharma landscape.
Related reading